Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 2019

View Archived Issues

A specific CNOT1 mutation results in impaired pancreatic and neurological development

Bacteriophages have "cascading effects" on microbiome

Clogged (nuclear) pores lead to febrile encephalopathy

First-in-human data presented for the nanotherapeutic compound NU-0129

Preliminary results from phase I study of MORAb-202 in patients with FRA-positive solid tumors

Clinical data show potential for improved renal transplant outcomes with CFZ-533

Deciphera adds first-in-class autophagy inhibitor to pipeline

Phase II data presented for NS-0200 in obesity

VTS-270 does not show efficacy in phase II/III study in type C Niemann-Pick disease

Eli Lilly initiates phase I study of its bispecific antibody LY-3434172

FDA approves Keytruda for two new indications

FDA clears IND for Sleeping Beauty TCR-T-cell therapy trial

Pharming initiates phase I/II study of Ruconest in patients with pre-eclampsia

Topline 12-week data reported from an ongoing phase IIb study of seladelpar in NASH

Sanofi presents preliminary data from a first-in-human study of SAR-439859

NT-1195, a potential treatment for type 2 diabetes, shows promising preclinical results

Immunicum reports partial responses in phase I/II trial of ilixadencel in GIST

Bristol-Myers Squibb patents TYK2 inhibitors

Evestra divulges LIF and MDM2 inhibitors

Tenebio opens enrollment in phase I study of TNB-383B in relapsed or refractory multiple myeloma

Bayer and and The Broad Institute present MCL1 inhibitors

DKFZ and Bayer identify AhR antagonists

CuroGene Life Sciences divulges recombinant vectors for macular degeneration

Gut microbe enzymes can convert blood from type A to type O

BARDA contract supports Mapp's development of MBP-091 for Marburg virus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...